Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410433 | 0.95 | MKNK1 (0.39) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410500 | 0.88 | MKNK1 (0.35) | MKNK1GRM5GRM4MKNK2NMT1 | |
| SCHEMBL12410511 | 0.87 | RIPK2 (0.39) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410482 | 0.86 | ADORA2A (0.36) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410579 | 0.86 | RIPK2 (0.38) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410507 | 0.84 | MKNK1 (0.35) | MKNK1RIPK2GRM5GRM4MKNK2 | |
| SCHEMBL12410535 | 0.83 | RIPK2 (0.35) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410509 | 0.83 | GRM4 (0.41) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410504 | 0.82 | RIPK2 (0.41) | MKNK1RIPK2ADORA2AADORA2BADORA1 | |
| SCHEMBL12410530 | 0.77 | MKNK1 (0.37) | MKNK1RIPK2ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066518-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9066518-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-2488030-B1 | 1-(PYRID-3-YL)-PYRAZOLES AND 1-(PYRIMID-5-YL)-PYRAZOLES AS PEST CONTROLLERS | BAYER CROPSCIENCE AG (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20140221362-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221362-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20110166143-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166143-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2011045224-A1 | 1- (PYRID-3-YL) -PYRAZOLE AND 1- (PYRIMID-5-YL) -PYRAZOLE AS PESTICIDE | BAYER CROPSCIENCE AG (DE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221362-A1 | Heterocyclic Compounds as Pesticides | DDT, ACHE, BCHE | MKNK1 2220/4885RIPK2 1635/4885ADORA2A 3858/4885 |
| US-20110166143-A1 | Heterocyclic Compounds as Pesticides | DDT, ACHE, BCHE | MKNK1 2220/4885RIPK2 1635/4885ADORA2A 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.